Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 27, 2023

Comparison of Clinical Outcomes After Osimertinib vs First-Generation EGFR-TKIs in Patients With TKI-Untreated EGFR-Mutated NSCLC With Leptomeningeal Metastases

ESMO Open

 

Additional Info

ESMO Open
Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases
ESMO Open 2023 Jul 28;8(4)101594, K Tamura, T Yoshida, K Masuda, Y Matsumoto, Y Shinno, Y Okuma, Y Goto, H Horinouchi, N Yamamoto, Y Ohe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading